蒼耳亭
| 中文名稱 | 蒼耳亭 |
|---|---|
| 中文同義詞 | 蒼耳亭(標準品);蒼耳亭;蒼耳亭(反式);蒼耳亭對照品;(3AR,7S,8AS)-7-甲基-3-亞甲基-6-((E)-3-氧代丁-1-烯-1-基)-3,3A,4,7,8,8A-六氫 2H-環(huán)庚并[B]呋喃-2-酮;順式蒼耳亭;蒼耳亭,10 MM DMSO 溶液 |
| 英文名稱 | xanthatin |
| 英文同義詞 | 2H-Cyclohepta[b]furan-2-one,3,3a,4,7,8,8a-hexahydro-7-Methyl-3-Methylene-6-(3-oxo-1-buten-1-yl)-,(3aR,7S,8aS)-;(3aR)-3,3aα,4,7,8,8aβ-Hexahydro-7β-methyl-3-methylene-6-(3-oxo-1-butenyl)-2H-cyclohepta[b]furan-2-one;(3aR)-3-Methylene-7β-methyl-6-(3-oxo-1-butenyl)-3,3aα,4,7,8,8aβ-hexahydro-2H-cyclohepta[b]furan-2-one;2H-Cyclohepta[b]furan-2-one, 3,3a,4,7,8,8a-hexahydro-7-methyl-3-methylene-6-[(1E)-3-oxo-1-buten-1-yl]-, (3aR,7S,8aS)-;(3aR,7S,8aS)-7-methyl-3-methylidene-6-[(E)-3-oxobut-1-enyl]-4,7,8,8a-tetrahydro-3aH-cyclohepta[b]furan-2-one;( - ) - xanthatin;(3aR,7S,8aS)-7-methyl-3-methylidene-6-[(1E)-3-oxobut-1-en-1-yl]-3,3a,4,7,8,8a-hexahydro-2H-cyclohepta[b]furan-2-one;(3aR,7S,8aS)-7-Methyl-3-methylene-6-((E)-3-oxobut-1-en-1-yl)-3,3a,4,7,8,8a-hexahydro-2H-cyclohepta[b]furan-2-one |
| CAS號 | 26791-73-1 |
| 分子式 | C15H18O3 |
| 分子量 | 246.3 |
| EINECS號 | |
| 相關(guān)類別 | 標準品;植物提取物;對照品;中藥對照品;精細化工;倍半萜;chemical reagent;pharmaceutical intermediate;phytochemical;reference standards from Chinese medicinal herbs (TCM).;standardized herbal extract;標準品 -中藥標準品;標準品，對照品;獨家化合物;化工衍生物;倍半萜內(nèi)酯 |
| Mol文件 | 26791-73-1.mol |
| 結(jié)構(gòu)式 |  |
蒼耳亭 性質(zhì)
| 熔點 | 114.5-115° |
|---|---|
| 比旋光度 | D30 -20° (ethanol) |
| 儲存條件 | 2-8°C |
| 溶解度 | DMSO: 2mg/mL, clear |
| 形態(tài) | powder |
| 沸點 | 444.3±45.0 °C(Predicted) |
| 密度 | 1.10±0.1 g/cm3(Predicted) |
| 顏色 | white to beige |
蒼耳亭（標準品）用于含量測定、鑒別、藥理實驗、活性篩選等。
抗菌、消炎作用、祛風散熱,除濕解毒。蒼耳子的毒性源于其富含的倍半帖內(nèi)酯類化合物,這類 成分常含有α,β不飽和y內(nèi)酯結(jié)構(gòu),是其生物活性的一個主要基團。研究表明，從蒼耳屬(Xanthium L.)植物(如蒼耳 子)中提取得到的倍半黏內(nèi)酯化合物蒼耳亭( Xanthatin),在 體內(nèi)外實驗中均顯示出較強的抗腫瘤活性,其對非小細胞肺 癌的生長存在顯著的抑制作用,且對正常肺上皮細胞生長影響較小。
Xanthatin 從 Xanthium strumarium 葉子中提取，誘導細胞凋亡 (apoptosis)。Xanthatin 通過抑制 PGE2 的合成和 5-脂氧合酶的活性而顯示出抗炎活性。Xanthatin 抑制布魯氏菌的 IC50 值為 2.63 μg/ mL，對寄生蟲特異性錐蟲硫磷還原酶具有不可逆的弱抑制作用。IC50: apoptosis; 3.8 μM (VEGFR2 kinase); 2.63?μg/mL ( T. b. brucei )
Xanthatin?is against T. b. brucei with an?IC 50 value of 2.63?μg/mL and exhibits weak irreversible inhibition of parasite specific trypanothione reductase.Xanthatin (0-40 μM; 24 hours) has obscure inhibition effect on the proliferation of HUVEC in the absence of VEGF.Xanthatin (5-40 μM; 24 hours) inhibits breast cancer cell proliferation in a dose responsive manner. Xanthatin inhibits HCC1937, MDA-MB-415, SK-BR-3, MCF-7 and MDA-MB-231 with IC 50 values of 81 μM, 31 μM, 38 μM, 30 μM, and 17 μM, respectively.Xanthatin (0-10 μM; 24 hours) dose dependently suppresses the phosphorylation of STAT3 (Ser727), at the same time, it also results in a rapid dephosphorylation of down-stream kinases of STAT3, including PI3K and Akt, including PI3K (p-PI3K p85 tyr458 ) and Akt.
Cell Proliferation Assay
| Cell Line: | HUVEC cells |
| Concentration: | 0 μM, 5 μM, 10 μM, 15 μM, 20 μM, 30 μM, 40 μM |
| Incubation Time: | 24 hours |
| Result: | Inhibited cell growth from dose 10 μM in the presence of vEGF. |
Cell Viability Assay
| Cell Line: | HCC1937, MDA-MB-415, SK-BR-3, MCF-7 and MDA-MB-231 cells |
| Concentration: | 5, 10, 15, 20, 30, and 40 μM |
| Incubation Time: | 24 hours |
| Result: | Inhibited breast cancer cell growth. |
Western Blot Analysis
| Cell Line: | HUVEC cells |
| Concentration: | 0, 3, and 10 μM |
| Incubation Time: | 24 hours |
| Result: | Inhibited VEGFR2 downstream signaling pathways and blocked VEGF-induced STAT3 activation in HUVEC. |
Xanthatin (intragastric administration; 20 mg/kg; once daily; 25 days) leads to significant inhibition of tumor volume. And this compound is well-tolerated and exhibits no significant difference in weight compares to the vehicle group.
| Animal Model: | Transplanted MDA-MB-231 cells into mice and constucted human breast cancer xenograft mouse model |
| Dosage: | 20 mg/kg; once daily; 25 days |
| Administration: | Intragastric administration |
| Result: | Supressed tumor growth and tumor angiogenesis in vivo. |
藥理藥效:抗菌、消炎作用。